Beam Therapeutics Inc. 10-Q Summary
Business context and reporting period
Beam Therapeutics is a preclinical biotechnology company developing precision genetic medicines based on base-editing technology and multiple delivery modalities, including ex vivo electroporation, lipid nanoparticles and AAV vectors. This report covers the three months ended March 31, 2021, filed May 11, 2021. The company had 61.7 million common shares outstanding at March 31, 2021 and 62.6 million as of May 4, 2021.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| License revenue | $6 thousand | $6 thousand | No change |
| Research and development expense | $190.1 million | $21.5 million | +$168.6 million |
| General and administrative expense | $10.3 million | $6.8 million | +$3.5 million |
| Loss from operations | $(200.4) million | $(28.4) million | $(172.0) million |
| Net loss | $(201.6) million | $(30.5) million | $(171.1) million |
| Net loss per share | $(3.35) | $(1.03) | Worsened |
| Net cash used in operating activities | $(38.6) million | $(27.4) million | $(11.2) million |
Comprehensive loss was $201.6 million. No product revenue was generated, and the company expects operating losses and negative operating cash flow for the foreseeable future. There is no meaningful operating margin because revenue was nominal relative to operating expenses.
At March 31, 2021, cash and cash equivalents were $97.2 million, marketable securities were $406.2 million and total cash, cash equivalents and marketable securities were approximately $503.5 million. Restricted cash was $14.8 million. Total assets were $693.2 million and total liabilities were $270.8 million. The company had $7.0 million of equipment financing liabilities and $129.7 million of operating lease liabilities; it also recorded $73.1 million of derivative liabilities and $36.8 million of contingent consideration liabilities. Accumulated deficit was $599.2 million.
Investing cash outflows were $279.6 million, primarily reflecting $268.8 million of net purchases of marketable securities and $11.5 million of property and equipment purchases. Financing cash inflows were $253.3 million, primarily from the January 2021 private placement, which generated $252.0 million of net proceeds.
Material changes versus the prior comparable period
- Research and development expense increased by $168.6 million, primarily because the Guide Therapeutics acquisition generated a $155.0 million non-cash in-process research and development charge.
- Guide was acquired in February 2021 for $120.0 million of Beam common stock. Former Guide holders may receive up to $100.0 million of technology milestones and $220.0 million of product milestones, payable in Beam common stock. The related contingent consideration liability was $36.8 million at March 31, 2021.
- General and administrative expense increased 51%, driven by higher personnel, insurance, legal, intellectual property and stock-based compensation costs.
- Beam raised $260.0 million in gross proceeds through a January 2021 private placement of 2.8 million shares at $93.00 per share.
- Property and equipment increased to $52.0 million from $38.5 million, while operating lease right-of-use assets increased to $106.8 million from $86.9 million.
- Stock-based compensation increased to $4.6 million from $2.8 million. Unrecognized compensation expense totaled $132.4 million at March 31, 2021.
Guidance, outlook, risks and unusual items
- Management expects to file an IND for BEAM-101 in the second half of 2021, begin IND-enabling studies for BEAM-102 and BEAM-201 during 2021, and nominate its first liver-portfolio development candidate in the second half of 2021.
- The company expects its cash, cash equivalents and marketable securities at March 31, 2021 to fund operations for at least the next 12 months, but states that additional financing will be required to continue operations and pursue growth.
- In April 2021, Beam established a $300.0 million at-the-market equity program. Through May 4, 2021, it had sold 12,607 shares for $0.8 million of net proceeds.
- In May 2021, success payments of $15.0 million each were calculated for Harvard and the Broad Institute. Beam elected to settle both obligations in common stock, with issuance expected in June 2021.
- Beam expects to invest up to $83.0 million over five years in a 100,000-square-foot cGMP manufacturing facility in North Carolina, which it expects to be operational by the first quarter of 2023. The initial estimated minimum lease payments for this facility were $63.9 million.
- The company remains entirely dependent on research, preclinical development, regulatory approvals, future financing and potential collaborations. It has no committed external source of funds and may never generate significant product revenue or achieve profitability.
- Key risks include clinical and technical failure, manufacturing and regulatory delays, intense competition, COVID-19-related disruption, dependence on key personnel, dilution from equity financing and milestone settlements, and substantial intellectual-property disputes involving CRISPR and gene-editing patents.
- COVID-19 did not significantly affect operations in Q1 2021, but management stated that future effects remain uncertain.
Most important facts for investors to verify
- Whether planned IND filings and IND-enabling studies for BEAM-101, BEAM-102 and BEAM-201 remain on schedule.
- The cash-burn rate and expected operating runway after the Guide acquisition, manufacturing investment and continued pipeline expansion.
- The probability, timing and potential dilution associated with Guide technology and product milestones.
- The number and value of shares issued to settle the Harvard and Broad Institute success payments.
- Progress, total cost and timing of the North Carolina cGMP manufacturing facility.
- Results of ongoing patent interference, opposition and other intellectual-property proceedings that could affect the company’s ability to commercialize its platform.
- Whether future equity issuance, including the ATM program, materially increases share-count dilution.